Edition:
United Kingdom

People: Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

5.95USD
23 Aug 2019
Change (% chg)

$0.06 (+1.02%)
Prev Close
$5.89
Open
$5.85
Day's High
$6.09
Day's Low
$5.81
Volume
539,224
Avg. Vol
715,521
52-wk High
$37.21
52-wk Low
$4.98

Muehl, Daniel 

Mr. Daniel W. (Dan) Muehl is Executive Vice President of Finance, Principal Accounting Officer and Principal Financial Officer of the Company. Mr. Muehl was appointed our Principal Accounting Officer and Principal Financial Officer in March 2016 and has served as our Executive Vice President of Finance since February 2019 and, prior to that, as our Senior Vice President of Finance from September 2016 and Vice President of Finance since 2015. Previously, Mr. Muehl was the Chief Financial Officer of biotechnology company Somalogic, Inc. from 2014 to 2015 and prior to that the Chief Financial Officer of bio-industrial company OPX Biotechnologies, Inc. from 2010 to 2014. He earned a Bachelor of Science degree in accounting from the University of Massachusetts—Amherst and received his Certified Public Accountant certificate in 1990.

Basic Compensation

Total Annual Compensation, USD 580,169
Restricted Stock Award, USD 525,870
Long-Term Incentive Plans, USD --
All Other, USD 403,544
Fiscal Year Total, USD 1,509,580

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Ginger Graham

357,479

Patrick Mahaffy

6,267,460

Gillian Ivers-Read

1,764,020

Daniel Muehl

1,509,580

Paul Gross

--

Ann Bozeman

--
As Of  31 Dec 2018